No CTE/No AD | Low CTE | High CTE | Low AD | Int/High AD | CTE+AD | p | |
---|---|---|---|---|---|---|---|
Sample size (n) | 41 | 18 | 43 | 23 | 56 | 11 | |
Age at death (S.E.M.) | 74.1 (3.0)d | 64.6 (4.6)f,d,e | 74.8 (1.3)d | 86.7 (1.1)a,b,c | 81.1 (1.3)b | 79.6 (2.8)b | <.001 |
Age range (max-min) | 101–17 | 89–25 | 90–53 | 95–72 | 98–54 | 70–100 | |
Cohort | |||||||
FHS | 13 | 1 | 0 | 10 | 13 | 1 | |
UNITE | 17 | 17 | 43 | 1 | 12 | 10 | |
HOPE | 11 | 0 | 0 | 12 | 31 | 0 | |
Sex m/f (%male) | 33/8 (80.5%)c,e | 18/0 (100%)e | 43/0 (100%)a,d,e | 14/9 (60.9%)c | 27/29 (48.2%) a,b,c | 10/1 (90.9%) | <.001 |
CTE stage | |||||||
Stage I | 0 | 6 (33.3%) | 0 | 0 | 0 | 1 (9.1%) | |
Stage II | 0 | 12 (66.7%) | 0 | 0 | 0 | 1 (9.1%) | |
Stage III | 0 | 0 | 18 (41.9%) | 0 | 0 | 0 | |
Stage IV | 0 | 0 | 25 (58.1%) | 0 | 0 | 9 (81.8%) | |
Braak Score | |||||||
0 | 15 (36.6%) | 7 (38.9%) | 1 (2.3%) | 0 | 0 | 0 | |
I-II | 12 (29.3%) | 5 (27.8%) | 4 (9.3%) | 6 (26.1%) | 0 | 0 | |
III-IV | 14 (34.1%) | 5 (27.8%) | 31 (72.1%) | 17 (73.9%) | 7 (12.5%) | 1 (9.1%) | |
V-VI | 0 | 1 (5.6%) | 7 (16.3%) | 0 | 49 (87.5%) | 10 (90.9%) | |
CERAD Score | |||||||
0 | 41 (100%) | 14 (77.8%) | 21 (48.8%) | 0 | 0 | 0 | |
1 | 0 | 4 (22.2%) | 22 (51.2%) | 22 (95.7%) | 8 (14.3%) | 1 (9.1%) | |
2 | 0 | 0 | 0 | 1 (4.3%) | 26 (46.4%) | 6 (54.5%) | |
3 | 0 | 0 | 0 | 0 | 22 (39.3%) | 4 (36.4%) | |
FTLD pathology | 10 (27.7%)d,e | 5 (27.8%)d,e | 6 (14.6%) | 0 (0%)a,b | 3 (5.4%)a,b | 2 (18.2%) | <.05 |
Tau | 9 (25%) | 5 (27.8%) | 6 (14.6%) | 0 | 2 (4.3%) | 2 (18.2%) | |
TDP 43 | 1 (2.7%) | 5 (27.8%) | 4 (9.8%) | 0 | 2 (4.3%) | 1 (9%) | |
n total | 36 | 18 | 41 | 15 | 46 | 11 | |
LBD pathology | 0.31 | ||||||
Brainstem | 2 (4.4%) | 1 (5.6%) | 6 (14%) | 2 (13.3%) | 2 (4.34%) | 0 (0%) | |
Limbic/neocortical | 4 (9.8%) | 2 (11.1%) | 10 (23.3%) | 1 (6.6%) | 8 (17.4%) | 4 (36.4%) | |
n | 36 | 18 | 43 | 15 | 46 | 11 | |
Contact sports play | Yes 12 (29.2%) | Yes 17 (94.4%) | Yes 43 (100%) | Yes 0 | Yes 9 (16%) | Yes 10 (90%) | .013 |
No 2 (4.8%) | No 0 | No 0 | No 1 (4%) | No 1 (1.7%) | No NA | ||
Missing 27 (70.7%) | Missing 1 (5.6%) | Missing 0 | Missing 22 (96%) | Missing 46 (82%) | Missing 1 (9.1%) | ||
CSF hemoglobin (S.E.M.) | 481.0 (106.6) | 648.3 (261.2) | 465.1 (106.5) | 555.6 (183.6) | 386.5 (93.1) | 370.5 (192.7) | 0.85 |
n | 36 | 11 | 33 | 23 | 49 | 11 | |
Postmortem interval (hours) (S.E.M)95% CI | 23.2 (3.15)b 16.82–29.56 | 46.6 (6.34)a,d,e 33.2–59.99 | 33.88(3.02)e 27.77–39.98 | 21.40 (3.85)b 13.43–29.37 | 20.70 (2.31)b,c 16.1–25.32 | 24.99 (4.05) 15.98–34.0 | <.001 |
N | 40 | 18 | 42 | 23 | 56 | 11 | |
PMI range (Max-Min) | 80.5.00–1.75 | 101.00–5.5 | 96.00–2.00 | 96.00–5.83 | 99.15–1.75 | 48.00–3.00 | |
RIN (S.E.M.) n | 6.2 (0.2) 35 | 5.76 (0.5) 16 | 5.6 (0.2) 31 | 5.7 (0.5) 12 | 5.8 (0.2) 39 | 4.7 (0.4) 10 | 0.15 |
pH (S.E.M.) n | 6.14 (0.08) 26 | 6.14 (0.10) 14 | 6.17 (0.1) 24 | 6.07 (0.13) 11 | 6.08 (0.06) 36 | 5.97 (0.8) 6 | 0.83 |